ImmunityBio Stock Surges for Tenth Straight Day on Revenue Jump
ImmunityBio shares rose 30.79% Thursday, marking a 10-day rally after reporting a 700% increase in preliminary 2025 revenue for its drug Anktiva.
Topic
Latest reporting and analysis tagged with biotechnology.
ImmunityBio shares rose 30.79% Thursday, marking a 10-day rally after reporting a 700% increase in preliminary 2025 revenue for its drug Anktiva.
Erasca Inc. shares surged 15% to a three-year high after four investment firms issued bullish ratings and raised price targets, citing positive clinical trial data.
Rigel Pharmaceuticals announced preliminary Q4 2025 revenue of $69.8 million and full-year revenue of $294.3 million, with a 2026 projection of $275-$290 million. Analyst Joseph Pantginis maintained a Buy rating.
Erasca's general counsel sold 120000 shares for $670800 on Jan 7, reducing direct holdings by 82.72% while retaining 360000 options.
Adrian Rawcliffe, a director at Wave Life Sciences, sold 42,000 shares for approximately $630,000 on December 8, 2025, through an exercise-and-sell transaction under a prearranged trading plan.
ADMA Biologics announced Q3 2025 revenue of $134.2 million, up 12% year-over-year, with profitability expanding sharply. The company raised its full-year revenue guidance to at least $510 million.
Erasca Inc. shares jumped over 20% to a multi-year high after HC Wainwright raised its price target to $11. The move followed the company's presentation of preliminary clinical data at a healthcare conference.
Moderna's stock jumped over 17% after the company projected 2025 revenue of $1.9 billion at a healthcare conference, with the CEO citing cost reductions and product launches.
Arcturus Therapeutics, a biotech firm, is drawing investor interest with its mRNA therapies for cystic fibrosis and OTC deficiency. Wall Street analysts project significant stock growth.